ArriVent BioPharma Cash Flow Statement
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.73+0.02 (+0.12%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ArriVent BioPharma free cash flow
In fiscal 2025, ArriVent BioPharma generated -$160.6 million of operating cash flow. That left free cash flow of -$160.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
ArriVent BioPharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -166.31M | -80.49M | -69.33M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | -3.03M | — | — |
| Stock-Based Compensation | 12.52M | 3.21M | 895.00K |
| Change in Working Capital | -3.75M | 5.61M | 2.90M |
| Operating Cash Flow | -160.59M | -70.21M | -55.84M |
| Investing Cash Flow | -71.23M | -192.47M | — |
| Financing Cash Flow | 203.06M | 186.58M | 42.86M |
| Net Change in Cash | -28.75M | -76.10M | -12.98M |
| Free Cash Flow | -160.59M | -70.21M | -55.84M |
This table shows 3 annual periods of ArriVent BioPharma's cash flow statement, from FY 2025 back to FY 2023, across 9 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AVBP's reporting calendar. What is a cash flow statement?